Neurocrine Biosciences Inc (NBIX)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 11:30 AM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow NBIX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on NBIX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
NBIX at a glance
Key statistics
$14.43B
Market capitalization
- Previous close
- $142.00
- Open
- $140.87
- Day range
- $140.87 – $142.77
- Volume
- 169.5K
- Average volume (30 sessions)
- 1.36M
- Shares outstanding
- 101.65M
- Price / earnings
- 20.5
- Earnings per share
- $6.94
- Price / book
- 3.9
- Price / sales
- 4.3
- Beta (1 year, vs SPY)
- 0.65
Where the price sits in its year
52-week range
30% of the range
- Below the 52-week high
- -24.0%
- Above the 52-week low
- +15.8%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $140.11+1.3%
- 50-day average
- $148.27-4.2%
- 200-day average
- $147.02-3.4%
Between the conventional 30 and 70 bands.
+5.1%
1 week
-1.4%
1 month
-17.8%
3 months
+0.1%
Year to date
+1.4%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with NBIX
NBIX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on NBIX.
See the plans →
Every planScreen names like NBIX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on NBIX
Put NBIX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on NBIX
See whether there is an open premium alert on NBIX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
NBIX headlines
- Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
GlobeNewswire Inc. · Aug 26, 2026
- Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
GlobeNewswire Inc. · Apr 12, 2026
- Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market
Benzinga · Apr 6, 2026
- Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance
Benzinga · Feb 12, 2026
- Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
GlobeNewswire Inc. · Jun 2, 2025
- Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
GlobeNewswire Inc. · May 28, 2025
- Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Benzinga · Jan 28, 2025
- Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Benzinga · Dec 16, 2024
SEC Form 4, most recent first
Insider filings
Gano Kyle
−3.4K
Chief Executive Officer, Director · Shares withheld for tax
$528.96K · Sep 11, 2026
GORMAN KEVIN CHARLES
−7.8K
Director · Shares withheld for tax
$1.22M · Sep 11, 2026
BENEVICH ERIC
+6.3K
Chief Commercial Officer · Grant or award
· Sep 11, 2026
Lippoldt Darin
+4.5K
Chief Legal Officer · Grant or award
· Sep 11, 2026
Keswani Sanjay Chandru
−2.1K
Chief Medical Officer · Shares withheld for tax
$329.94K · Sep 11, 2026
ABERNETHY MATT
+5.0K
Chief Financial Officer · Grant or award
· Sep 11, 2026
Boyer David W.
+3.6K
Chief Corp. Affairs Officer · Grant or award
· Sep 11, 2026
Cooke Julie
−1.9K
Chief Human Resources Officer · Shares withheld for tax
$302.44K · Sep 11, 2026
About Neurocrine Biosciences Inc
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- San Diego, CA
- Employees
- 2,500
- Listed since
- May 23, 1996
- Website
- neurocrine.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.